OverviewSuggest Edit

Celyad is a biopharmaceutical company, specialized in cell therapy and developing of technologies to treat severe diseases with poor prognosis. The Company focuses on immuno oncology, cardiology, and medical devices.

TypePublic
Founded2007
HQMont-Saint-Guibert, BE
Websitecelyad.com

Latest Updates

Employees (est.) (Feb 2019)80
Job Openings1
Revenue (FY, 2017)€3.5 M(-58%)
Share Price (Mar 2017)€20.2 (-3%)

Key People/Management at Celyad

Christian Homsy

Christian Homsy

Executive Director, CEO
Patrick Jeanmart

Patrick Jeanmart

CFO, Investor Relations
Jean-Pierre Latere

Jean-Pierre Latere

Chief Operating Officer (COO)
Frederic Lehmann

Frederic Lehmann

VP Clinical Development and Medical Affairs
David Gilham

David Gilham

VP Research & Development
Philippe Dechamps

Philippe Dechamps

Chief Legal Officer
Show more

Celyad Office Locations

Celyad has offices in Mont-Saint-Guibert and Boston
Mont-Saint-Guibert, BE (HQ)
2 Rue Edouard Belin
Boston, US
2 Seaport Ln
Show all (2)

Celyad Financials and Metrics

Celyad Revenue

Embed Graph
View revenue for all periods
Celyad's revenue was reported to be €3.54 m in FY, 2017 which is a 58.5% decrease from the previous period.
EUR

Revenue (FY, 2017)

3.5m

Revenue growth (FY, 2016 - FY, 2017), %

(58.5%)

Gross profit (FY, 2017)

3.0m

Gross profit margin (FY, 2017), %

85.5%

Net income (FY, 2017)

(56.4m)

EBIT (FY, 2017)

(52.9m)

Market capitalization (22-Mar-2017)

190.4b

Closing stock price (22-Mar-2017)

20.2

Cash (31-Dec-2017)

23.3m

EV

190.4b
Celyad's current market capitalization is €190.4 b.
EURFY, 2015FY, 2016FY, 2017

Revenue

3.0k8.5m3.5m

Revenue growth, %

284000%(58%)

Cost of goods sold

1.0k53.0k515.0k

Gross profit

2.0k8.5m3.0m
EURFY, 2015FY, 2016FY, 2017

Cash

100.2m48.4m23.3m

Accounts Receivable

549.0k1.4m233.0k

Current Assets

109.4m85.4m36.4m

PP&E

1.1m3.6m3.3m
EURFY, 2015FY, 2016FY, 2017

Net Income

(29.1m)(23.6m)(56.4m)

Depreciation and Amortization

273.0k760.0k966.0k

Accounts Payable

1.1m(740.0k)(2.5m)

Cash From Operating Activities

(27.3m)(24.7m)(44.4m)
EURY, 2017

EV/EBIT

-3.6 k x

EV/CFO

-4.3 k x

Revenue/Employee

44.0k

Financial Leverage

1.6 x
Show all financial metrics

Celyad Online and Social Media Presence

Embed Graph

Celyad News and Updates

Celyad Announces October and November 2019 Investor Conference Schedule

MONT-SAINT-GUIBERT, Belgium, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that management plans to participate at the following investor…

Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting

MONT-SAINT-GUIBERT, Belgium, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that clinical data on the company’s pipeline of candidates will be p…

Celyad Announces Pricing of $20.0 Million Global Offering

MONT-SAINT-GUIBERT, Belgium, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced the pricing of a global offering of 2,000,000 ordinary shares, comp…

Celyad Announces Launch of Proposed Global Offering

Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, announced today that it intends to offer and sell, subject to market and other conditions, up to 2,000,000 ordinary sha…

Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process

MONT-SAINT-GUIBERT, Belgium, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced the successful administration of CYAD-01 produced with the Op…

Celyad Reports Half Year 2019 Financial Results and Second Quarter Business Highlights

MONT-SAINT-GUIBERT, Belgium, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced its consolidated financial results for the first half of 2019 and pr…
Show more

Celyad Frequently Asked Questions

  • When was Celyad founded?

    Celyad was founded in 2007.

  • Who are Celyad key executives?

    Celyad's key executives are Christian Homsy, Patrick Jeanmart and Jean-Pierre Latere.

  • How many employees does Celyad have?

    Celyad has 80 employees.

  • What is Celyad revenue?

    Latest Celyad annual revenue is €3.5 m.

  • What is Celyad revenue per employee?

    Latest Celyad revenue per employee is €44.3 k.

  • Who are Celyad competitors?

    Competitors of Celyad include Alnylam Pharmaceuticals, Sorrento Therapeutics and Moderna Therapeutics.

  • Where is Celyad headquarters?

    Celyad headquarters is located at 2 Rue Edouard Belin, Mont-Saint-Guibert.

  • Where are Celyad offices?

    Celyad has offices in Mont-Saint-Guibert and Boston.

  • How many offices does Celyad have?

    Celyad has 2 offices.